CervoMed Q3 net loss narrows as R&D costs drop after RewinD-LB trial completion
CRVO•CervoMed’s third-quarter net loss narrowed to $5.9 million, below the $7.04 million analyst consensus, as research and development costs fell after the RewinD-LB trial was completed.
1. Costs and outlook
CervoMed said lower research and development expenses mainly reflected completion of the RewinD-LB trial and lower personnel and trial costs. It recognized no grant revenue in the quarter, reflecting completion of prior trial funding. The company aims to secure a partner to advance neflamapimod into a Phase 3 DLB trial, expects to present 24-week nfvPPA biomarker data at CTAD 2026 in November, and expects topline data from its Phase 2a RESTORE stroke trial by the end of 2026.
